🔒 Premium Content Alert – This buzzing stock opinion is accessible only to
Premium members
Discover an exclusive list and analysis of the stocks that are trending on social
medias—accessible only to our Premium subscribers. With a keen focus on the stocks
that are setting social media ablaze, this weekly feature offers an invaluable lens
through which to evaluate market movers. Say goodbye to the endless scroll through
social media timelines; we curate the buzz so you can invest your time as wisely as
your money. Unlock Premium Now.
After spinoff, now just pharma and medical technologies/devices. One of 2 AAA-rated US companies (the other is MSFT). Pristine balance sheet forever. Divvy increases for 62 consecutive years, all from free cashflow. Crazy-cheap valuation of 14-15x PE, partly due to ongoing talc litigation. Yield is 3.34%.
(Analysts’ price target is $170.36)Recent press release was like none other. Company stated talc litigation based on fake science; if the other side won't settle, JNJ will litigate each and every case separately. He suspects this is a ploy to force a settlement. Expects it to be over by year's end.